Test Price
2,800 AED✅ Home Collection Available
CLCNKA Gene Sequencing for Bartter Syndrome Type 4B (Genetic Test) in UAE | 2,800 AED
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited NGS processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic post-test clinical guidance in result interpretation and genetic counselling.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
This genetic test analyzes the CLCNKA gene to identify pathogenic variants associated with Bartter syndrome type 4B, a rare autosomal recessive renal salt‑wasting disorder. Early and accurate diagnosis enables targeted management of electrolyte imbalances and prevents long‑term renal complications.
| Feature | Our Test (NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% sensitivity for pathogenic variants | High accuracy but limited to known hotspots |
| Method | Next Generation Sequencing (NGS), full gene coverage | Sanger sequencing, targeted exons only |
| Speed (TAT) | 3–4 Weeks | 4–6 Weeks |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I emphasize that CLCNKA sequencing results must be correlated with clinical phenotype, electrolyte profiles, and family history. Variants of uncertain significance may require segregation studies and follow‑up counselling. This test does not replace comprehensive nephrological evaluation.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Medication Advisory Card
Medication Warning
Do not discontinue or alter any prescribed medications (e.g., potassium supplements, diuretics, NSAIDs) without consulting your managing nephrologist. Sudden discontinuation may precipitate life‑threatening electrolyte imbalances.
Exclusion Criteria & Red Flags
Exclusion Criteria
- Patients with active infections or recent blood transfusions (within 90 days) should postpone testing.
- Individuals unable to provide informed consent or those who decline mandatory genetic counselling.
Emergency Red Flags
- If you experience severe dehydration, muscle cramps, palpitations, or cardiac arrhythmia, seek emergency medical attention immediately.
Patient FAQ & Clinical Guidance
1. What is the CLCNKA gene test for Bartter syndrome type 4B?
This genetic test identifies disease‑causing mutations in the CLCNKA gene, which leads to Bartter syndrome type 4B—a rare inherited kidney disorder that causes salt wasting, low potassium, and metabolic alkalosis. Early diagnosis helps guide treatment and reduces renal damage.
2. How is the test performed?
A standard blood draw (EDTA tube) is performed by a trained phlebotomist. Alternatively, extracted DNA or FTA card samples are accepted. The sample is sent to our ISO‑accredited laboratory for Next Generation Sequencing, which reads the entire CLCNKA gene.
3. Who should consider this test?
Individuals with clinical suspicion of Bartter syndrome (e.g., unexplained hypokalemia, metabolic alkalosis, hypercalciuria) and those with a family history of the condition. Genetic counselling before and after testing is mandatory per UAE law.
4. What are the risks or limitations?
The test has minimal physical risk (only blood draw). Limitations include the possibility of variants of uncertain significance (VUS) that may require further family studies. The test does not detect pathogenic variants in other genes that may cause similar phenotypes.
5. How do I prepare for the test?
No special preparation is needed. Avoid blood transfusion for 90 days prior. Bring a detailed clinical history and any previous genetic reports. Arrange for a genetic counsellor consultation if not already scheduled.
UAE Regulatory & Data Privacy Adherence
This service fully complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability. All genetic data is encrypted, access‑controlled, and never shared without explicit written consent. Our DHA facility license (No. 1143) ensures regular audit compliance.
Clinical & Logistical Metadata
| Test Name | CLCNKA Gene Sequencing for Bartter Syndrome Type 4B |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or Extracted DNA or FTA Card |
| Methodology Used | Next Generation Sequencing (NGS) – Full Gene Coverage |
| ICD-10-CM Code | E26.81, Z84.81, Z14.8 |
| LOINC Code | 94257-2 |
| DHA Facility License & Address | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians